• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study Compares Tigecycline Testing Accuracy Across Critical Drug-Resistant Bacterial Pathogens

by
November 9, 2026
in Health
Reading Time: 7 mins read
0
Study Compares Tigecycline Testing Accuracy Across Critical Drug-Resistant Bacterial Pathogens

Study Compares Tigecycline Testing Accuracy Across Critical Drug-Resistant Bacterial Pathogens

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comparative diagnostic evaluation published in the Annals of Clinical Microbiology and Antimicrobials reveals major performance discrepancies among standard laboratory susceptibility tests used to guide tigecycline therapy against carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii. Tigecycline remains one of the primary therapeutic options against these life-threatening pathogens, yet clinical laboratories struggle with methodological instability across testing platforms. To evaluate routine alternatives to broth microdilution, the recognized gold standard that is often too complex and labor-intensive for high-throughput diagnostic workflows, researchers conducted a head-to-head comparison examining six susceptibility testing techniques across three international interpretive criteria. The investigation demonstrated that test reliability depends heavily on the specific bacterial species tested, the formulation of testing reagents, and the regulatory breakpoint standards applied, with commercial gradient strips exhibiting exceptional concordance in carbapenem-resistant Klebsiella pneumoniae while failing to deliver acceptable precision in carbapenem-resistant Acinetobacter baumannii.

The clinical urgency surrounding reliable antibiotic testing stems from the severe burden posed by multidrug-resistant Gram-negative organisms. In the World Health Organization global priority list of antibiotic-resistant bacteria, carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii are designated as pathogens of critical priority due to their high incidence, treatment complexity, and alarming mortality rates. Research cited in the study highlights that hospital-acquired pneumonia accounts for 38.8 percent of isolated strains in hospital wards, with carbapenem-resistant Enterobacterales representing 19.3 percent and Klebsiella pneumoniae emerging as the dominant pathogen responsible for 14.2 percent of bloodstream infections, followed by Acinetobacter baumannii at 9.6 percent. Surveillance data from the China Antimicrobial Surveillance Network covering 2005 through 2025 document that carbapenem resistance rates in Klebsiella pneumoniae rose from roughly 3 percent to over 24 percent for imipenem and meropenem, while resistance in Acinetobacter baumannii jumped from approximately 31 to 39 percent up to more than 76 percent. Longitudinal clinical studies reinforce the lethal nature of these infections, with 28-day mortality reaching 48.3 percent in carbapenem-resistant Klebsiella pneumoniae bloodstream infections compared to 5.83 percent in susceptible cases, and 30-day mortality climbing to 56.1 percent among intensive care unit patients infected with carbapenem-resistant Acinetobacter baumannii.

Conducted at the Fourth Medical Center of the People’s Liberation Army General Hospital in Beijing, the diagnostic investigation evaluated 53 clinical isolates of carbapenem-resistant Klebsiella pneumoniae and 47 clinical isolates of carbapenem-resistant Acinetobacter baumannii gathered between December 8, 2021, and January 20, 2023. Institutional review board and local ethical committees approved the investigation. The isolate demographics reflected real-world clinical presentations: among the Klebsiella pneumoniae samples, 66 percent were recovered from patients with pneumonia, 21 percent from patients experiencing trauma or extensive burns, 11 percent from urinary tract infections, and 2 percent from bloodstream infections. For the Acinetobacter baumannii cohort, 83 percent of isolates originated from pneumonia specimens, while 17 percent were isolated from patients suffering from trauma or extensive burn injuries. All gathered bacterial strains had initially exhibited intermediate or resistant classifications during routine screening on automated microbiology systems, necessitating rigorous confirmation against reference standards.

The experimental protocol systematically compared six distinct diagnostic approaches: the reference broth microdilution method, automated testing using the Vitek2 Compact 60 platform with N334 cards for Klebsiella pneumoniae and N335 cards for Acinetobacter baumannii, standard Kirby-Bauer disk diffusion using 15-microgram tigecycline disks, a modified Kirby-Bauer disk diffusion method incorporating six microliters of a specialized buffer solution containing ethylenediaminetetraacetic acid disodium salt and sodium hydroxide, the Autobio Diagnostics Epsilometer test strip, and Liofilchem minimum inhibitory concentration test strips. Testing procedures adhered strictly to Clinical and Laboratory Standards Institute guidelines. Escherichia coli ATCC 25922 served as the reference quality control strain, with validity defined by inhibition zone diameters between 20 and 27 millimeters and minimum inhibitory concentrations within 0.03 to 0.25 micrograms per milliliter. The measurement scale spanned 0.016 to 256 micrograms per milliliter for gradient strips and 0.032 to 32 micrograms per milliliter for broth microdilution. Experienced laboratory personnel conducted manual inoculations and measurements independently across different time points, utilizing freshly prepared Mueller-Hinton agar plates and vernier calipers to minimize operator error.

To evaluate diagnostic concordance, the authors analyzed results against breakpoint thresholds published by the United States Food and Drug Administration, the European Committee on Antimicrobial Susceptibility Testing, and the British Society for Antimicrobial Chemotherapy, noting that the Clinical and Laboratory Standards Institute has not established tigecycline breakpoints in document M100-34. Evaluation metrics complied with standard regulatory criteria, tracking essential agreement within one doubling dilution, categorical agreement across interpretive classifications, very major error rates signifying false susceptibility, major error rates denoting false resistance, minor error rates reflecting intermediate discrepancies, and Cohen Kappa coefficients of statistical concordance. Acceptable performance limits set by the Clinical and Laboratory Standards Institute require essential agreement and categorical agreement of at least 90 percent, very major error rates no greater than 1.5 percent, major error rates no higher than 3.0 percent, and minor error rates capped at 10.0 percent.

When evaluated against the Food and Drug Administration interpretive standards, the Autobio Epsilometer gradient test demonstrated outstanding diagnostic precision for carbapenem-resistant Klebsiella pneumoniae, achieving a categorical agreement of 98.1 percent and an essential agreement of 92.5 percent against reference broth microdilution. The method registered zero very major errors and zero major errors, accompanied by a minor error rate of only 1.9 percent and a Kappa coefficient of 0.658, establishing substantial statistical agreement that satisfied all Clinical and Laboratory Standards Institute criteria. The Liofilchem minimum inhibitory concentration strips also exhibited acceptable concordance with an 84.9 percent agreement rate when compared with the Epsilometer test, but displayed a slightly elevated minor error rate of 13.2 percent and a categorical agreement of 86.8 percent against broth microdilution. In sharp contrast, the automated Vitek2 platform completely failed to accurately report susceptibility, generating a zero percent susceptibility rate under Food and Drug Administration criteria, a 47.2 percent major error rate, and a 52.8 percent minor error rate, demonstrating that automated alerts cannot be trusted without secondary manual confirmation.

A critical technical breakthrough documented in the trial involved stabilizing the chemical testing microenvironment of the standard Kirby-Bauer disk diffusion test. Conventional disk diffusion has historically performed terribly for tigecycline, but the addition of six microliters of buffering solution containing ethylenediaminetetraacetic acid disodium salt and sodium hydroxide to stabilize agar pH markedly improved physical inhibition zone diameters and diagnostic accuracy. In carbapenem-resistant Klebsiella pneumoniae, the modified disk diffusion technique expanded the mean inhibition zone diameter by 3.2 plus or minus 0.8 millimeters compared to the standard disk assay, while in carbapenem-resistant Acinetobacter baumannii, the zone diameter increased by an average of 3.6 plus or minus 0.8 millimeters. When evaluated under Food and Drug Administration criteria for Klebsiella pneumoniae, the modified method elevated interpretive accuracy from a negligible 1.9 percent up to 62.3 percent. Furthermore, the modified method eliminated major errors entirely from 17.0 percent down to zero percent, dropped minor errors from 83.0 percent to 39.6 percent, and lifted categorical agreement from zero percent to 60.4 percent, confirming that environmental pH fluctuations represent a major driver of false resistance in standard disk assays.

Despite the remarkable diagnostic success of gradient diffusion strips in Klebsiella pneumoniae, the testing platforms encountered severe degradation in performance when applied to carbapenem-resistant Acinetobacter baumannii. Under Food and Drug Administration breakpoints, the accuracy of the Epsilometer test plummeted from 98.1 percent down to 68.1 percent, matching an identical low accuracy rate of 68.1 percent observed for the alternative strip assay. When compared to broth microdilution, the Epsilometer test registered an essential agreement of only 68.1 percent and a categorical agreement of 68.1 percent in Acinetobacter baumannii, failing to meet benchmark thresholds. While very major and major error rates remained at zero percent, minor errors surged to 31.9 percent, and the resulting Kappa coefficient dropped to 0.082, representing very weak statistical concordance. Paired statistical testing revealed that reference broth microdilution produced significantly lower minimum inhibitory concentrations than the gradient strips in Acinetobacter baumannii, showing an average decrease of 0.73 micrograms per milliliter compared to the Epsilometer strip and a 1.39 microgram per milliliter decrease compared to the Liofilchem strip, emphasizing that interspecies biological variations disrupt gradient strip diffusion.

Applying European Committee on Antimicrobial Susceptibility Testing breakpoints resulted in substantial interpretive divergences and degraded diagnostic reliability across all manual and automated platforms. Under European guidelines, reference broth microdilution classified only 47.2 percent of the carbapenem-resistant Klebsiella pneumoniae isolates as susceptible, in contrast to the 100 percent susceptibility identified under Food and Drug Administration criteria and 77.4 percent observed under British standards. When measured against European benchmarks, the Epsilometer test achieved a categorical agreement of only 69.8 percent, failing clinical standards by generating an intolerable 11.3 percent very major error rate and an 18.9 percent major error rate. Automated Vitek2 testing under European guidelines similarly exhibited an excessive major error rate of 47.2 percent, while the alternative gradient strip yielded false resistance rates reaching 47.2 percent. Agreement between standard and modified disk diffusion was low at 28.3 percent, demonstrating that European breakpoint thresholds align poorly with manual gradient diffusion and automated testing platforms.

Diagnostic assessments evaluated under the British Society for Antimicrobial Chemotherapy criteria demonstrated similar methodological limitations. While the Epsilometer test maintained acceptable very major error rates of zero percent and major error rates of 1.9 percent for Klebsiella pneumoniae, its minor error rate rose to 20.8 percent, pulling overall categorical agreement down to 77.4 percent. The alternative gradient test produced a 9.4 percent major error rate and an 18.9 percent minor error rate, confirming the superior reliability of the Epsilometer strip. In carbapenem-resistant Acinetobacter baumannii, British interpretive standards caused diagnostic fidelity to collapse completely: categorical agreement dropped to 48.9 percent for the Epsilometer strip and plummeted to 12.8 percent for the alternative strip method, accompanied by major error rates near 19 percent and minor error rates reaching 70.2 percent. The automated Vitek2 platform generated a staggering 77.4 percent major error rate under British criteria, reaffirming that automated hardware systematically misclassifies susceptible isolates as falsely resistant.

The study highlights how media characteristics, manufacturing variations, and underlying bacterial genetics shape susceptibility testing outcomes. Minimum inhibitory concentrations measured by the two commercial gradient strips differed significantly, with Liofilchem strips generating higher readings than Autobio strips across both pathogen cohorts, illustrating that strip matrix materials and manufacturing techniques directly impact antibiotic diffusion through agar. Genotypic diversity documented in published clinical literature further complicates testing, as carbapenem-resistant Klebsiella pneumoniae typically harbors blaKPC or blaNDM resistance determinants while carbapenem-resistant Acinetobacter baumannii predominantly expresses blaOXA-23 and related carbapenemases that may alter membrane physiology and biofilm production. The authors noted that their investigation was limited by a moderate sample size and an absence of genotypic sequencing for specific resistance enzymes. Nevertheless, the clinical findings provide clear practical guidance: while the buffered modified disk diffusion test provides a valuable first-line screening option for primary laboratories, the cost-effective domestic Epsilometer strip interpreted under Food and Drug Administration breakpoints provides an outstanding substitute for broth microdilution in Klebsiella pneumoniae, whereas Acinetobacter baumannii isolates demand dedicated reference verification to avoid substantial diagnostic misclassification.

Subject of Research: Comparative evaluation of tigecycline antimicrobial susceptibility testing methods for carbapenem-resistant bacterial pathogens

Article Title: Comparative evaluation of tigecycline susceptibility testing methods for carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii

Article References: Shi, Y., Li, S., He, L., Wang, H., Shang, Y., Zhang, K., Han, X., Wei, Y., Chu, W., & Xiong, Y. (2026). Comparative evaluation of tigecycline susceptibility testing methods for carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Annals of Clinical Microbiology and Antimicrobials, 25(1), Article 32. https://doi.org/10.1186/s12941-026-00869-0

Image Credits: AI Generated

DOI: 10.1186/s12941-026-00869-0

Keywords: tigecycline susceptibility, carbapenem-resistant Klebsiella pneumoniae, carbapenem-resistant Acinetobacter baumannii, broth microdilution, E-test, modified Kirby-Bauer test, antimicrobial resistance, diagnostic microbiology, Comparative, evaluation, tigecycline, susceptibility

News Source: Ophelia Keating. (November 9, 2026). Study Compares Tigecycline Testing Accuracy Across Critical Drug-Resistant Bacterial Pathogens. Scienmag.

Tags: Antimicrobial Resistancebroth microdilutioncarbapenem-resistant Acinetobacter baumanniicarbapenem-resistant Klebsiella pneumoniaeComparativediagnostic microbiologyE-testevaluationmodified Kirby-Bauer testsusceptibilitytigecyclinetigecycline susceptibility
Share12Tweet7Share2ShareShareShare1

Related Posts

Clinical Task Involvement Linked to Higher Job Satisfaction Among Community Pharmacists

Clinical Task Involvement Linked to Higher Job Satisfaction Among Community Pharmacists

November 17, 2026
Voronoi Density Influences Human Fibroblast Adhesion on Porous Titanium Implants

Voronoi Density Influences Human Fibroblast Adhesion on Porous Titanium Implants

November 17, 2026

Community Trust Presents Opportunities to Strengthen Non-Communicable Disease Prevention in Ethiopia

November 17, 2026

A Third of Barcelona Detainees With Active Hepatitis C Are Undiagnosed

November 17, 2026

POPULAR NEWS

  • De Novo Unbalanced X;14 Translocation Linked to Turner Syndrome Phenotype

    De Novo Unbalanced X;14 Translocation Linked to Turner Syndrome Phenotype

    29 shares
    Share 12 Tweet 7
  • Nepal Survey Finds Stable Drug-Resistant Tuberculosis Rates Alongside Rising Fluoroquinolone Resistance

    29 shares
    Share 12 Tweet 7
  • Systematic Review Finds No Clear Mortality Benefit Across Six Sepsis Treatments

    29 shares
    Share 12 Tweet 7
  • Surgical Internet of Medical Things Faces Cyber Threats Endangering Patient Safety

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Clinical Task Involvement Linked to Higher Job Satisfaction Among Community Pharmacists

Gellan Gum and Hydrocolloids Control Anthocyanin Dissolution in Vegan Jelly Candies

Voronoi Density Influences Human Fibroblast Adhesion on Porous Titanium Implants

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.